A state-owned lab in Brazil, with the help of privately-owned local companies, has begun manufacturing its own generic version of Gilead Sciences's antiretroviral Viread (tenofovir), says the health ministry. The news comes two years after the national intellectual property institute, INPI, rejected Gilead Sciences's patent application for Viread.
A state-owned lab in Brazil, with the help of privately-owned local companies, has begun manufacturing its own generic version of Gilead Sciences's antiretroviral Viread (tenofovir), says the health ministry. The news comes two years after the national intellectual property institute, INPI, rejected Gilead Sciences's patent application for Viread.
Funed, the state-owned lab in Minas Gerais, registered the product earlier this month and says it should eventually be able...
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
